Davidson Capital Management Inc. Buys 6,333 Shares of iRadimed Corporation $IRMD

Davidson Capital Management Inc. lifted its stake in shares of iRadimed Corporation (NASDAQ:IRMD) by 11.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 63,017 shares of the medical equipment provider’s stock after acquiring an additional 6,333 shares during the period. Davidson Capital Management Inc.’s holdings in iRadimed were worth $5,433,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. BlackRock Inc. acquired a new position in iRadimed during the 2nd quarter worth approximately $92,485,000. Dimensional Fund Advisors LP boosted its holdings in iRadimed by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock worth $21,768,000 after acquiring an additional 9,017 shares during the period. Ranger Investment Management L.P. purchased a new position in iRadimed in the 2nd quarter worth approximately $9,398,000. Bank of New York Mellon Corp acquired a new stake in iRadimed in the second quarter valued at approximately $7,252,000. Finally, Sei Investments Co. grew its position in iRadimed by 17.2% in the first quarter. Sei Investments Co. now owns 74,304 shares of the medical equipment provider’s stock valued at $7,153,000 after acquiring an additional 10,908 shares in the last quarter. 92.34% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Needham & Company LLC initiated coverage on shares of iRadimed in a research note on Tuesday, September 22nd. They set a “hold” rating on the stock. Weiss Ratings cut shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, October 2nd. Finally, Wall Street Zen downgraded shares of iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $120.00.

iRadimed Price Performance

Shares of iRadimed stock opened at $89.37 on Friday. The business has a 50-day moving average of $86.18 and a 200-day moving average of $90.42. The company has a market capitalization of $1.14 billion, a PE ratio of 50.18 and a beta of 0.91. iRadimed Corporation has a 1-year low of $73.02 and a 1-year high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. iRadimed had a return on equity of 23.45% and a net margin of 26.70%. The business had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, equities analysts expect that iRadimed Corporation will post 1.98 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were paid a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Friday, August 14th. iRadimed’s dividend payout ratio (DPR) is 44.69%.

Insiders Place Their Bets

In other iRadimed news, Director Monty K. Allen sold 1,419 shares of iRadimed stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $86.41, for a total transaction of $122,615.79. Following the sale, the director directly owned 19,581 shares in the company, valued at $1,691,994.21. The trade was a 6.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 34.60% of the stock is currently owned by company insiders.

iRadimed Profile

IRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. The company focuses on addressing the challenges of providing continuous infusion therapy and patient monitoring while patients are undergoing MRI procedures.

Its products include the MRidium MRI-compatible infusion pump system, which is designed to deliver intravenous medications and fluids without interfering with MRI operations, and MRI-compatible patient-monitoring systems used to track vital signs during imaging.